R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Total Current Assets
ÂĄ2B
CAGR 3-Years
62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Current Assets
ÂĄ30.3B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Current Assets
ÂĄ7.1B
CAGR 3-Years
-7%
CAGR 5-Years
33%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Current Assets
ÂĄ19.8B
CAGR 3-Years
-3%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Current Assets
ÂĄ7.6B
CAGR 3-Years
-10%
CAGR 5-Years
19%
CAGR 10-Years
27%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Current Assets
ÂĄ5.2B
CAGR 3-Years
273%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Total Current Assets?
Total Current Assets
2B CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Total Current Assets amounts to 2B CNY.

What is R&G PharmaStudies Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
62%

Over the last year, the Total Current Assets growth was 11%. The average annual Total Current Assets growth rates for R&G PharmaStudies Co Ltd have been 62% over the past three years .

Back to Top